Tumour targeting

McDevitt et al. (2007) reported that the tumour-targeting CNT constructs were synthesised via sidewall covalent functionalisation using 1,3-dipolar cycloaddition to attach the antibody IgG, radiometal-ion chelates and fluorescent probes. 

Liu Z, Cai WB, He LN, NakayamaN, Chen K, Sun XM, Chen XY, Dai HJ (2007) In vivo biodistribution and highly efficient tumour targeting of carbon nanotubes in mice. Nat Nanotechnol 2 47-52. 

L19 scFv Fibronectin ED-B/Angiogenesis (ocular neovasculature and tumour targeting) [105,106,107]... 

Zhu et al. [57,58] applied PB-PK modelling to radiolabeUed tumour-targeted monoclonal antibodies for radioimmunodetection and radioimmunotherapy. 

C. Kosmas, H. Linardou, and A. A. Epenetos, Review Advances in monoclonal antibody tumour targeting, J. Drug Target 7 81-91 (1993). 

FitzGerald, K., Holliger, P., and Winter, G. (1997). Improved tumour targeting by disulphide stabilized diabodies expressed in Pichia pastoris. Protein Eng. 10, 1221-1225. 

Matzku, S. Krempel, H. Weckenmann, H.P. Schirrma-cher, V. Sinn, H. Strieker, H. Tumour targeting with antibody-coupled liposomes failure to achieve accumulation in xenografts and spontaneous liver metastases. Cancer Immunol. Immunother. 1990, 31, 285-291. 

Toncheva V, Schacht E, Ng SY, Barr J, Heller J (2003) Use of block copolymers of poly(ortho esters) and poly (ethylene glycol) micellar carriers as potential tumour targeting systems. J Drug Target 11 345-353... 

Greish K, Fang J, Inutsuka T, et al. Macromolecular therapeutics advantages and prospects with special emphasis on solid tumour targeting. Clin Pharmacokinet 2003 43 1089-1105. 

FROIDEVAUSX, S., et al.. Neuroendocrine tumour targeting Study of novel gallium-labelled somatostatin radiopeptides in a rat pancreatic tumour model, Int. J. Cancer 98 (2002) 930-937. 

ZAMORA, P.O., BENDER, H., KNAPP, EE, Jr., BIERSACK, H.J., Radiotherapy of intrathoracic carcinoma senografts with Re-RC-160, a somatostatin analogue. Tumour Targeting 2 (1996) 49-59. 

Rowlinson-Busza, G., Deonarain, M. P., and Epenetos, A. A. (1996) Comparison of intact monoclonal antibody, its F(ab )2 and Fab fragments and recombinant single chain Fv in a human tumour xenograft model. Tumour Targeting 2,37 48. 

Sharkey, R. M., Primus, F. J., Shochat, D., and Goldenberg, D. M. (1988) Comparison of tumour targeting of mouse monoclonal and goat polyclonal antibodies to carcinoembryonic antigen in the GW-39 human tumour-hamster host model. Cancer Res. 48, 1823-1828... 

Bagshawe, K. D., Sharma, S. K., Springer, C. J., and Antoniw, P. (1995) Antibody directed enzyme prodrug therapy a pilot-scale clinical trial. Tumour Targeting 1,17-30. 

Chappell, M. J. and Godfrey, K. R. (1990) Structural identifiability of a model developed for optimal tumour targeting by antibodies using the similarity transformation approach. University of Warwick Control and Instrument Systems Centre, Report No. 7. 

Thomas, G. D. (1995) Development of a model of tumour targeting to predict optimal conditions for therapy. MD Thesis, University of London, London. 

Nitin, K., Damle, E., Tumour-targeted chemotherapy with immunoconjugates of calicheamicin. Exp. Opin. Biol. Ther. 2004, 4(9), 1445-1452. 

Duncan, R. (1999) Polymer conjugates for tumour targeting and intracytoplasmic delivery. The EPR effect as a common gateway, Pharm Sci Technol Today 2(11), 441-449. 

K., Cassidy, J. and Duncan, R. (1991) Synthetic polymers conjugated to monoclonal antibodies vehicles for tumour-targeted drag delivery. Select. Cancer Ther. 7 59-13. 

Seymour, L.W. (1992) Passive tumour targeting of soluble macromolecules and drug conjugates. Crit. Rev. Therapeut. Drug Carr. Syst. 9 135-187. 

Mitra S, Gaur U, Ghosh P C, et al. (2001). Tumour targeted delivery of encapsulated dextran-doxorubicin conjugate using chitosan nanoparticles as carrier. J. Control. Rel. 74 317-323. 

Sat YN, Mahk N, Turton JT, Duncan R. Tumour targeting by the EPR effect comparison of three drug delivery system containing doxorubicin. Proceedings of the International S3unpo-sium on Controlled Release of Bioactive Materials 1999 26 44 5. 

---